Athira Pharma raises $204M in IPO, reaching ‘big milestone’ in fight against Alzheimer’s and other diseases
More than 5 million Americans have Alzheimer’s disease, and the number is projected to rise to nearly 14 million by 2050. Athira Pharma is on a mission to treat the debilitating disorder — and now it has additional capital and a bigger platform to pursue that goal as a public company. The Seattle biotech company on Friday morning became the third Washington state company to make its initial public offering this year, debuting on the Nasdaq under the ticker ATHA. “This is a big milestone,” Athira CEO Leen Kawas said Friday in an interview with GeekWire. The IPO marks an achievement for Kawas, who began building the foundation of Athira while earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago.